Medpace PE ratio MEDP
Share price divided by earnings per share over the last twelve months, since 2017.
- Today, Nov 2, 2026
- 38.0×
- 9-year median
- 34.5×
- Against its 9-year history
- 66th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 22.5× to 63.0×
- Peer median
- 41.2×
Medpace's PE ratio is 38.0× as of Nov 2, 2026: a share price of $648.14 against $17.05 of earnings per share over the last twelve months.
That is above its 9-year median of 34.5×, higher than on 66% of days in the last 9 years.
Over that time it ranged from 22.5× in May 2025 to 63.0× in Oct 2017.
The median for 10 diagnostics and research stocks of a similar size is 41.2×.
PE ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 38.0× | 25.8× | 42.7× |
| 2025 | 39.7× | 22.5× | 42.3× |
| 2024 | 29.9× | 27.2× | 46.0× |
| 2023 | 35.9× | 24.0× | 36.5× |
| 2022 | 32.6× | 24.9× | 38.9× |
| 2021 | 45.1× | 38.0× | 51.5× |
| 2020 | 42.6× | 25.2× | 45.5× |
| 2019 | 33.7× | 25.8× | 42.1× |
| 2018 | 31.0× | 28.3× | 56.8× |
| 2017 | 53.3× | 47.7× | 63.0× |
Against its peers
Companies in Medical - Diagnostics & Research nearest Medpace's size, closest first, today.
| Company | PE ratio |
|---|---|
| MEDPMedpace | 38.0× |
| RVTYRevvity | 72.2× |
| DGXQuest Diagnostics | 24.9× |
| LHLabcorp | 29.4× |
| BIOBio-Rad Laboratories | 44.4× |
| MTDMettler-Toledo International | 38.4× |
| ILMNIllumina | 44.0× |
| CAICaris Life Sciences | 86.8× |
| IQVIQVIA | 32.0× |
| WATWaters | 118× |
| AAgilent Technologies | 34.5× |
| Peer median | 41.2× |
Where Medpace ranks
What the PE ratio tells you
Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.
Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.
More on Medpace
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.